CMA to investigate the supply of bipolar drug* The CMA has opened an investigation into suspected anti-competitive practices in the supply of drugs used to treat bipolar disorder. The Competition and Markets Authority (CMA) will investigate whether the pharmaceutical company Essential Pharma has abused a dominant position in relation to lithium-based
The UK Competition Authority opens an investigation into alleged abuse of dominance in the supply of drugs used to treat bipolar disorder (Essential Pharma)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.